Stock Fundamentals

Company Information

Company Name
Liquidia Technologies Inc
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NASDAQ
ISIN: US53635D2027
CIK: 0001330436
CUSIP: 53635D202
Currency: USD
Full Time Employees: 216
Phone: 919 328 4400
Fiscal Year End: December
IPO Date: Jul 26, 2018
Description:

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.

Address:

419 Davis Drive, Morrisville, NC, United States, 27560

Directors & Officers

Name Title Year Born
Dr. Roger A. Jeffs Ph.D. CEO & Director 1962
Mr. Michael Kaseta COO & CFO 1976
Mr. Russell Schundler General Counsel & Corporate Secretary 1976
Mr. Scott Moomaw Chief Commercial Officer 1971
Dr. Rajeev Saggar M.D. Chief Medical Officer 1975
Ms. Dana Boyle Chief Accounting Officer 1985
Mr. Christian Perez Font Senior VP, Chief Compliance Officer & Associate General Counsel NA
Mr. Michael Post Senior Vice President of Marketing NA
Matt Snow Senior Vice President of Sales NA
Ms. Sarah Krepp SPHR Chief Human Resources Officer 1982

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Apr 17, 2026 Roger Jeffs N/A Sale 18.84K $40.60 $764.86K
Apr 15, 2026 Michael Kaseta N/A Sale 139.39K $40.14 $5.60M
Apr 15, 2026 Roger Jeffs N/A Sale 25.00K $40.14 $1.00M
Apr 14, 2026 Michael Kaseta N/A Sale 3.00K $40.00 $120.00K
Apr 14, 2026 Roger Jeffs N/A Sale 3.30K $40.00 $132.00K
Apr 13, 2026 Russell Schundler N/A Sale 13.69K $38.37 $525.36K
Apr 13, 2026 Scott Moomaw N/A Sale 10.55K $38.34 $404.37K
Apr 13, 2026 Sarah Krepp N/A Sale 4.56K $38.37 $174.85K
Apr 13, 2026 Roger Jeffs N/A Sale 32.74K $38.37 $1.26M
Apr 13, 2026 Rajeev Saggar N/A Sale 9.22K $38.37 $353.77K
Apr 13, 2026 Michael Kaseta N/A Sale 18.96K $38.37 $727.42K
Apr 13, 2026 Jason Adair N/A Sale 7.30K $38.37 $280.14K
Apr 13, 2026 Dana Boyle N/A Sale 5.10K $38.37 $195.73K
Apr 10, 2026 Michael Kaseta N/A Sale 23.82K $40.14 $956.17K
Apr 10, 2026 Roger Jeffs N/A Sale 21.43K $40.12 $859.89K
Apr 09, 2026 Michael Kaseta N/A Sale 133.79K $40.24 $5.38M
Apr 09, 2026 Roger Jeffs N/A Sale 25.00K $40.12 $1.00M
Mar 27, 2026 Stephen M Bloch N/A Sale 62.55K $35.94 $2.25M
Mar 23, 2026 Scott Moomaw N/A Sale 18.31K $36.79 $673.77K
Jan 26, 2026 Dana Boyle N/A Sale 1.58K $41.65 $65.81K

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Farallon Capital Management, L.L.C. 8.66M Mar 31, 2026 9.74% $1.86 0.00%
Caligan Partners LP 8.12M Mar 31, 2026 9.13% $20.39 0.00%
BlackRock Inc 5.49M Mar 31, 2026 6.18% $0.00 0.01%
Vanguard Group Inc 4.01M Dec 31, 2025 4.52% $0.00 1.33%
Findell Capital Management LLC 3.50M Mar 31, 2026 3.94% $38.71 22.82%
Opaleye Management Inc 2.55M Mar 31, 2026 2.86% $11.70 4.52%
Bank of America Corp 2.29M Mar 31, 2026 2.57% $0.01 18.70%
Geode Capital Management, LLC 1.93M Mar 31, 2026 2.17% $0.00 19.01%
State Street Corp 1.88M Mar 31, 2026 2.12% $0.00 4.02%
MPM Oncology Impact Management LP 1.41M Mar 31, 2026 1.58% $4.10 0.31%
Caprock Group Inc 1.37M Mar 31, 2026 1.54% $1.25 -23.36%
Susquehanna International Group, LLP 1.00M Mar 31, 2026 1.13% $0.00 281.94%
T. Rowe Price Associates, Inc. 953.15K Mar 31, 2026 1.07% $0.00 2,468.38%
D. E. Shaw & Co LP 873.07K Mar 31, 2026 0.98% $0.02 -47.64%
The Goldman Sachs Group Inc 811.99K Mar 31, 2026 0.91% $0.00 15.32%
Jane Street Group LLC 795.88K Mar 31, 2026 0.90% $0.00 90.57%
Eversept Partners, LP 677.39K Mar 31, 2026 0.76% $1.35 32.97%
BOOTHBAY FUND MANAGEMENT, LLC 625.05K Mar 31, 2026 0.70% $0.31 1.87%
Buckley Capital Advisors LLC 624.84K Mar 31, 2026 0.70% $16.95 -3.78%
FMR Inc 582.20K Mar 31, 2026 0.65% $0.00 53.88%

Shares Statistics

Shares Outstanding: 88.93M
Shares Float: 62.24M
% Insiders: 1,269.00%
% Institutions: 7,011.80%
Short % Float: 14.26%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Total Stock Mkt Idx Inv 2.09M 2.35% ▲ 0.31% Apr 30, 2026
2 iShares Russell 2000 ETF 1.54M 1.74% ▲ 0.85% Apr 30, 2026
3 Jupiter Merian Glb Eq AbsRet I USD Acc 1.23M 1.38% ▲ 0.00% Dec 31, 2025
4 Vanguard Institutional Extnd Mkt Idx Tr 775.01K 0.87% ▲ 0.83% Apr 30, 2026
5 Fidelity Small Cap Index 628.40K 0.71% ▲ 1.09% Feb 28, 2026
6 iShares Russell 2000 Growth ETF 538.13K 0.61% ▲ 0.98% Apr 30, 2026
7 Russell 2000 Equity Index Fund B 401.13K 0.45% ▼ 2.67% Dec 31, 2025
8 State St Russell Sm/Mid Cp® Indx SL Cl I 389.57K 0.44% ▲ 0.00% Apr 30, 2026
9 Fidelity Extended Market Index 366.17K 0.41% ▲ 2.10% Mar 31, 2026
10 Oberweis Micro-Cap Growth 357.20K 0.40% ▲ 11.21% Mar 31, 2026

Valuation Metrics

Enterprise Value: $5.19B
Trailing P/E: 324.18
Forward P/E: 28.33

Financial Highlights

Market Cap: $4.90B
EBITDA: $46.63M
P/E Ratio: $324.18
Book Value: $1.23
Earnings/Share: $0.17
Profit Margin: 7.74%
Operating Margin: 46.29%
ROA (TTM): 9.05%
ROE (TTM): 28.18%
Revenue (TTM): $288.06M
Revenue/Share (TTM): $3.32
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 4,158.50%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 1.40x 4.29x 0.86x -2.13x -4.44x
2024-12-31 4.43x 1.50x 0.66x -9.71x -1.00x
2023-12-31 4.85x 1.00x 0.60x -11.70x -0.67x
2022-12-31 11.34x 0.23x 0.30x -16.58x -0.60x
2021-12-31 8.36x 0.18x 0.30x -44.35x -0.41x
2020-12-31 5.63x 0.17x 0.29x -68.87x -0.21x
2019-12-31 3.34x 0.51x 0.49x -34.09x -0.41x
2018-12-31 4.85x 0.66x 0.62x -1.84x -0.38x
2017-12-31 0.18x -0.64x 3.27x -2.15x -1.42x
2016-12-31 0.26x -0.46x 3.15x -184.74x -0.56x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about LQDA.US!